Talal Ahmed Awad,Fatima Alfatih,Muhammad Shafiq,Mohnad Abdalla,Samia T. Al-Shouli,Amani Bashir,Maaweya E. Awadalla,Hassan A. Alhazmi,Mohammed Albratty,Hafiz A. Makeen,Asaad Khalid,Zaheer Ul-Haq,Talal Ahmed AwadFatima AlfatihMuhammad ShafiqMohnad AbdallaSamia T. Al-ShouliAmani BashirMaaweya E. AwadallaHassan A. AlhazmiMohammed AlbrattyHafiz A. MakeenAsaad KhalidZaheer Ul-Haqa Department of Biochemistry,Medicinal and Aromatic Plants and Traditional Medicine Research Institute,National Center for Research,Khartoum,Sudanb Department of Pharmaceutical Chemistry,Faculty of Pharmacy,Ibn Sina University,Khartoum,Sudanc H.E.J. Research Institute of Chemistry,International Center for Chemical and Biological Sciences,University of Karachi,Karachi,Pakistand Pediatric Research Institute,Children's Hospital Affiliated to Shandong University,Jinan,Shandong,Chinae Immunology Unit,Pathology Department,College of Medicine,King Saud University,Riyadh,Kingdom of Saudi Arabiaf College of Applied and Industrial Sciences,University of Bahri,Khartoum,Sudang Research Center,King Fahad Medical City,Riyadh,Saudi Arabiah Substance Abuse and Toxicology Research Centre,Jazan University,Jazan,Saudi Arabiai Department of Pharmaceutical Chemistry and Pharmacognosy,Faculty of Pharmacy,Jazan University,Jazan,Saudi Arabiaj Pharmacy Practice Research Unit,Clinical Pharmacy Department,Faculty of Pharmacy,Jazan University,Jazan,Saudi Arabiak Dr. Panjwani Center for Molecular Medicine and Drug Research,International Center for Chemical and Biological Sciences,University of Karachi,Karachi,Pakistan

Abstract:Diabetes mellitus (DM) remains one of the pivotal diseases that have drawn the attention of researchers recently and during the last few decades. Due to its devastating symptoms, attempts to develop new drugs with mild side effects have resulted in a number of drugs that are functioning through various mechanisms. Among these, Glycogen phosphorylase (GP) inhibitors emerged as a new strategy for combating DM. GP is an enzyme that regulates blood glucose levels; it catalyses the breakdown of glycogen to glucose-1-phosphate in the liver and tissues with high and fluctuating energy demands. In the present research, we evaluate the possibility of type 2 diabetes therapy with the help of chalcones which are known to have antidiabetic activities. For this purpose, 29 chalcones were modelled, synthesised and investigated for their inhibitory activity against GP using in-vitro methods. Compounds 1 , 2 , and 3 were found to be the most potent compounds with IC 50 values 26.6, 57.1 and 75.6 μM respectively. The observed results were further validated using in-silico methods. Molecular docking simulation revealed interaction patterns that explain the structure-activity relationships of the compounds with GP. Molecular dynamic (MD) simulation demonstrated a stable complex formation between compound 1 and GP through lower value and uniformity in root mean square deviation (RMSD) of the complex and root mean square fluctuation (RMSF) of the protein Cα.

Synthesis and Evaluation of C-28 Oleanolic Acid Derivatives As Inhibitors of Glycogen Phosphorylase

Pentacyclic triterpenes. Part 3: Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase

Design, Synthesis, and Evaluation of 3‐aryl‐4‐pyrrolyl‐maleimides As Glycogen Synthase Kinase‐3β Inhibitors

Synthesis and biological evaluation of oleanolic acid derivatives as PTP1B inhibitors.

Design, Synthesis and Evaluation of 7-Azaindazolyl-indolyl-maleimides As Glycogen Synthase Kinase-3Β (Gsk-3Β) Inhibitors

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.

Design, synthesis and biological evaluation of thieno[3,2- c ]pyrazol-urea derivatives as potent glycogen synthase kinase 3β inhibitors based on the DFG-out conformation

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors

ChemInform Abstract: Design, Synthesis, and Evaluation of 3-Aryl-4-pyrrolylmaleimides as Glycogen Synthase Kinase-3β Inhibitors.

Design, synthesis and evaluation of L-quebrachitol derivatives against α-glycosidase

Design, synthesis and structural-activity relationship studies of phanginin A derivatives for regulating SIK1-cAMP/CREB signaling to suppress hepatic gluconeogenesis

Synthesis and biological evaluation of novel ursolic acid analogues as potential α-glucosidase inhibitors

Studies of glycogen synthase kinase-3 inhibitors

Pentacyclic triterpenes. Part 1: the first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases

Discovery of Novel Glycogen Synthase Kinase-3Α Inhibitors: Structure-based Virtual Screening, Preliminary SAR and Biological Evaluation for Treatment of Acute Myeloid Leukemia.

Design, synthesis and inhibition evaluation of novel chalcone amide α-glucosidase inhibitors

Novel carbazole-oxadiazole derivatives as anti-α-glucosidase and anti-α-amylase agents: Design, synthesis, molecular docking, and biological evaluation

Synthesis, In Silico and Kinetics Evaluation of N-(β-d-glucopyranosyl)-2-arylimidazole-4(5)-carboxamides and N-(β-d-glucopyranosyl)-4(5)-arylimidazole-2-carboxamides as Glycogen Phosphorylase Inhibitors

Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes

Evaluation of chalcones as new glycogen phosphorylase inhibitors – an in-vitro and in-silico approach

Design, synthesis and biological evaluation of novel oxazole derivatives as potential hypoglycemic agents